Stella’s US clinic page shows example plans combining progesterone capsules with other care. The word capsule provides a clue about form, but it leaves the medicine unidentified. The surrounding treatments and patient stories can make the example feel complete even though no manufacturer or ingredient record is supplied.
This September 29, 2026 review examines the US offer and FAQ rather than assuming that the same conditions apply to Stella’s UK service. It separates the care example from product evidence and personal suitability. No appointment, app use, clinical result or delivered medicine was independently tested.
Read this article by section
The example names a form without naming the finished product
The US clinic page includes an example with estrogen gel and progesterone capsules, and another with estrogen spray, capsules and vaginal cream. These examples establish that progesterone capsules are part of the service’s published treatment discussion. They do not identify a specific brand, manufacturer or full formulation.
Our micronized meaning guide explains why the additional terminology cannot be assumed from the capsule form alone. The actual product would need to be named before its label could answer ingredient or regulatory questions. Pandia Health’s review contrasts a catalog that names a brand, while still leaving the selected dispensing unverified.
Several interventions cannot be credited to one ingredient
The sample plans place medicines beside interventions such as behavioral support, sleep-related exercises and other activities. Any accompanying improvement story does not isolate the effect of progesterone or establish an outcome for a particular capsule. This review treats those examples as provider presentation, not controlled comparative evidence.
That distinction also prevents the sample from becoming a recommended combination. A clinician would need to explain the role of each proposed intervention in the actual care plan. The page does not show that everyone with similar symptoms receives the same components or that adding another product produces a predictable additional benefit. No patient story is used here to rank the medicine’s effectiveness.
Regulated and approved should not be silently interchanged
Stella describes access to FDA-regulated hormonal and nonhormonal treatments. That is the provider’s wording; it does not identify the approval record for an unnamed progesterone capsule. This review neither upgrades that language into confirmation of a particular approved product nor interprets it as proof of compounding.
FDA’s compounding explanation and the bioidentical-and-approval guide show why finished-product status needs its own answer. The exact preparation matters before regulatory information can be applied. A service-level description cannot provide the manufacturer, full label or approval history for every medicine a clinician might consider, even when the offer is clearly a legitimate clinical pathway.
Route belongs to each medicine rather than the whole sample
In Stella’s examples, a gel, spray, capsule and vaginal cream are not presented as interchangeable names for one hormone. Summaries need to preserve the medicine attached to each form. The presence of several routes within a plan is not evidence that progesterone is supplied through all of them.
The oral, vaginal and topical guide addresses this distinction without giving alternative-use instructions. Wisp’s review considers a different menu containing progesterone and other named oral options. Both examples show why an accurate record needs the active ingredient and the form together, instead of treating the entire menopause menu as a single medicine specification.
The professional visit and the support tools do different work
Stella’s FAQ describes clinician visits, preferred-pharmacy prescribing and access to an app and coaching. Its US service age range is 35–70. That program condition does not establish that a medicine is appropriate for someone merely because their age falls within it.
Coaching and digital support are also different from identifying a dispensed product or making a clinical prescribing decision. A question about an ingredient list or proposed formulation needs the relevant clinician or pharmacist, not an inference from a wellness feature. The reviewed US record cannot establish international prescribing, a particular state appointment or any personal eligibility beyond the provider’s need to assess the person seeking care.
A consultation average does not price the capsule
The FAQ lists self-pay prices of $200 for the initial consultation and $90 for follow-up. Its reported $45 average copayment for insured visits is an average, not a guaranteed charge. Prescribed medicines are obtained separately through the pharmacy.
These units should remain distinct when the service is compared with a provider advertising a monthly medicine price. The sample capsule does not carry a verified quantity or pharmacy cost, and the reviewed pages do not resolve the complete cancellation or refund terms for a selected appointment. An actual quote would need to identify the professional service, applicable insurance, any additional care and the separately dispensed products.
The missing label is a question to resolve, not a reason to invent one
The Prometrium label provides an example of a named oral micronized product with defined ingredients and indications. It is not evidence that Stella’s example capsules are Prometrium or share every labeled property. Assigning that label would make the review appear more specific than the service record allows.
Stella’s actual offering can still be assessed for its US clinical pathway, published visit prices and additional support. The product-level conclusion remains limited: capsules are shown in examples, while the exact preparation is unresolved. A clinician’s explanation and dispensing information are needed before the reader can connect the sample’s language to a real medicine and evaluate its own evidence.
Documents behind the details
Read the source for the product, use and context it actually describes. A source type is not a rating of a provider.
- Stella: US virtual menopause clinicUS provider clinical service and example plans; examples do not establish a universal oral preparation or individual outcome · Checked 2026-09-29
- FDA: Understanding the Risks of Compounded DrugsFederal regulatory explanation; compounded preparations are not FDA-approved, no inference about inspection or quality of a named pharmacy · Checked 2026-09-29
- Stella US: frequently asked questionsDated US provider age range, visit fees, pharmacy and coaching scope; no exact capsule ingredients, guaranteed reimbursement or UK offer inferred · Checked 2026-09-28
- DailyMed: Prometrium progesterone capsule label, updated July 23, 2026Official structured label for the named oral product; chemical identity, micronization, formulation-specific ingredients and indications, not evidence of a reviewed provider supplying it · Checked 2026-09-29